Hypogonadotropic hypogonadism in non-functioning pituitary adenomas: impact of intervention by Diana Margarida Patrício de Carvalho Monteiro
2013/2014 
Diana Margarida Patrício Carvalho Monteiro 
Hypogonadotropic hypogonadism 
in non-functioning pituitary adenomas: 
impact of intervention 
março, 2014 
Mestrado Integrado em Medicina 
 
Área: Endocrinologia 
 
Trabalho efetuado sob a Orientação de: 
Professor Doutor Davide Carvalho 
 
Trabalho organizado de acordo com as normas da revista: 
Pituitary 
Diana Margarida Patrício Carvalho Monteiro 
Hypogonadotropic hypogonadism  
in non-functioning pituitary adenomas: 
impact of intervention 
março, 2014 
 
 
  
 
 
 
 
 
 
 
 
 
 
Dedicatória 
 
 
Aos meus pais 
Ao meu irmão 
Ao meu namorado 
 
 
1 
 
 
 
 
 
 
 
Hypogonadotropic hypogonadism in non-functioning 
pituitary adenomas: impact of intervention 
 
 
Diana Monteiro
1
, Romana Vieira
2
 and Davide Carvalho
1,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro,   
4202-451  Porto, Portugal 
2
Department of Rheumatology, Centro Hospitalar S. João, Porto, Portugal 
3
Department of Endocrinology, Diabetes and Metabolism , Centro Hospitalar S. João , 
Porto, Portugal 
 
 
Diana Monteiro 
Email: diana_monteiro_@hotmail.com  
Telephone: (+351) 96 53 28 559 
 
 
 
 
 
 
2 
 
Abstract 
Purpose: Determine the prevalence of hypogonadotropic hypogonadism (HH) among patients with non-
functioning pituitary adenoma (NFPA) and the impact of surgical intervention on it. Determine the 
prevalence of erectile dysfunction (ED) on male patients with NFPA, its association with HH and the 
response to testosterone replacement therapy (TRT). 
Methods: Retrospective evaluation of gonadal function in 109 NFPA patients (45 males), with a mean 
age of 51.8 years, diagnosed on the last 10 years. ED questionnaire applied to 34 male patients. 
Results: Male patients with NFPA were significantly older (males 58.1±15.8 vs 47.4±16.94; p=0.001). 
Most patients had macroadenomas (67%, p=0.001) and only a minority is incidentaloma (19%, p<0.001). 
Prevalence of HH was 40% (60% on males, 25% on females; p<0.001). Surgery was performed in 54% of 
all patients (71% of males, 42% of females; p=0.03). After intervention, 14% worsened, 69% maintained 
previous function and 17% improved. On the questionnaire, 76% reported having ED, 54% of which had 
HH and 21% were under TRT. Of the patients under TRT, 79% still have ED. Median age of patients 
with ED was significantly higher [with ED 65 vs without 49 years; p=0.012). There was no BMI 
difference between patients with or without TRT (28.0 vs 27.4). 
Conclusions: Prevalence of NFPA was higher on older patients (71% older than 40 years). Males were 
older, had more HH and surgery. There was no significant improvement of pituitary function with surgery 
(17%) and 13% became iatrogenic HH. TRT had a low efficacy to improve ED in these patients. 
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Introduction: 
Approximately 14% of all intracranial tumors are pituitary adenomas [1]. These benign tumors are 
classically divided according to their secreting pattern: functioning and non-functioning adenomas. 
Functioning adenomas secrete excessive amounts of pituitary hormones, leading to symptoms associated 
to that hypersecretion. On the other hand, non-functioning adenomas (NFPA) do not secrete biologically 
active hormones, therefore having a silent evolution [2,3]. The subtlety of the clinical features may delay 
the diagnosis [3]. If not found incidentally, they most often produce symptoms associated with their 
growth, compressing adjacent anatomical structures, such as the optic pathways and oculomotor nerves, 
producing visual deficits, stretching the diaphragma sellae and the sellar dura, resulting in headaches, or 
compressing the pituitary itself [4,5]. Due to compression of  pituitary tissue, pituitary stalk and its 
vascular supply, partial or total hypopituitarism may occur, resulting in deficit of  production of some or 
all pituitary hormones [6]. The most common pituitary deficit in these patients is hypogonadism [7]. 
Hypogonadotropic hypogonadism (HH) is due to reduced levels of pituitary gonadotropins (Follicle-
Stimulating-Hormone (FSH) and Luteinizing-Hormone (LH)), either from congenital or acquired 
hypothalamic or pituitary defects, that lead insufficient gonadal function [8].  Female patients with HH 
may present with menstrual cycle abnormalities, infertility or decreased libido [9]. Male patients with HH 
manifest impaired testicular function with problems on sperm production and testosterone secretion, 
resulting in infertility, weight gain, diminished physical strength, behavior changes, decreased libido or 
erectile dysfunction (ED) (inability to attain and or maintain penile erection sufficient for satisfactory 
sexual performance [10]) [11,12].  Surgery and radiotherapy are treatment options used to remove or 
reduce the tumor when the expansion of the mass impairs patients’ quality of life. Neurological 
symptoms, such as visual impairment or headache, and hypopituitarism may improve or disappear with 
these treatment options. However, some patients will experience worsening of symptoms due to the 
intervention [3]. In patients that maintain HH after surgical treatment, testosterone replacement therapy 
(TRT) plays major role in symptomatic treatment [13]. As for weight gain, physical strength, libido and 
ED, they may improve with TRT [12]. Accurate and systematic detection of these situations on male 
patients with HH is vital to introduce proper treatment that will improve quality of life. 
The aims of this study were: to determine the prevalence of HH among patients with NFPA and the post-
surgery outcome on pituitary gonadotropins secretion (PGS); to recognize factors of better or worse 
outcome, to determine if HH is associated with higher BMI and if there is a decrease in BMI with the 
improvement of pituitary function; to determine the prevalence of ED on the male patients with NFPA, its 
association with HH and the impact of TRT. 
 
 
Patients and Methods: 
Patients 
 
All patients with NFPA followed in our Department between 2003 and December 2013 were 
retrospectively assessed. NFPA was defined by the absence of signs, symptoms or laboratorial findings of 
hormone hypersecretion of TSH, cortisol, GH or PRL. Although some patients showed small increases of 
prolactin due to pituitary stalk compression, they were also comprised. Patients with incidentally 
discovered sellar lesions were also included.  
A total of 112 patients (47 males and 65 females) with NFPA were selected, 3 of which (2 males and 1 
female) were excluded due to absence of pre-surgical data.  
The Body Mass Index (BMI) was determined before and after surgery and compared. Of the 109 patients, 
only 87 had BMI evaluation before surgery due to lack of either weight or height data. Of the 59 patients 
subjected to surgery only 52 had BMI evaluation. 
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Methods 
 
Information of the patients’ gender, age, weight, height, intervention (surgery and/or radiotherapy) and 
hormonal analytical data (FSH, LH, total testosterone, free testosterone, oestradiol and responses to 
GnRH test) were recorded. Tumors were divided according to size in microadenomas (<10mm) and 
macroadenomas (>10mm). 
Patients were first classified in 2 groups: normal PGS (normal) and hypogonadotropic hypogonadism 
(HH). Females in menopause with hypergonadotropic hypogonadism were classified as “normal”, since 
this is the physiologic response and translates a functionally normal pituitary. The hormone levels and 
weight recorded were from the last evaluation before surgery and the first evaluation within 3 to 9 months 
after surgery for the operated patients. The recorded levels for the patients that did not undergo surgery 
were from the last known evaluation. The vast majority of patients were tested by our lab. Patients 
evaluated until 2006 had the determination of FSH, LH, oestradiol and total testosterone made by 
chemiluminescence on Abbott – Architect. After 2006 they were determined using 
electrochemiluminescence on Cobas e411. On both periods free testosterone was measured by 
radioimmunoassay. Used reference ranges were the ones provided by the respective laboratory at the 
given moment, for the patient’s gender and age. 
In male patients HH was defined if:  
– Testosterone was low and: if both FSH and LH were low; if LH was low; if FSH and LH were within 
the normal reference range, since the gonadotropins were inappropriately normal (the normal response to 
low levels of testosterone would be to be elevated) [7,14] 
– Testosterone was normal but the patient was under TRT: if both FSH and LH were low; if LH was 
low [15] 
In female patients HH was defined if: 
– In pre-menopause: oestradiol was low and both FSH and LH were low; if FSH and LH were 
inappropriately normal (as explained for males) 
– In post-menopause oestradiol is low by definition (hypergonadotropic hypogonadism). To be 
classified as HH both FSH and LH had to be 20% below the inferior limit of the reference range for that 
group (higher than pre-menopause females) 
 
If patients were included in the HH group, response to synthetic Gonadotropin-Releasing-Hormone 
(GnRH) was analyzed. The GnRH test was done by administering 100 μg of synthetic GnRH and drawing 
blood for FSH and LH values at 0, 15, 30, 60, 90 and 120 minutes. A positive response to the GnRH was 
established if FSH raised 1.5 times the basal value or if LH raised 2 times the basal value,  in females, 3 
times the basal value, in males [16,17]. If there was a response to the stimulation with GnRH, the cause of 
the HH was deficient hypothalamic hormone secretion and the pituitary remained functional. A non-
response to GnRH stimulus translated a non-functioning pituitary, with or without hypothalamic damage. 
Of the 43 patients with HH before intervention (27 males and 16 females), only 30 (21 males and 9 
females) had data from GnRH stimulation. Of the 32 patients with HH after surgery (20 males and 12 
females) only 17 (9 males and 8 females) had data from GnRH stimulation.  
 
The Androgen Deficiency in Aging Males (ADAM) questionnaire, validated to assess ED was applied to 
all living male patients. The questionnaire was self-applied, sent by post accompanied with the informed 
consent. An extra envelope was added for the patients to send the signed informed consent and the 
questionnaire to the Hospital without cost. The questionnaire is showed on Table 11.  
A positive result on the questionnaire was defined as an affirmative answer (‘‘yes’’) to questions 1 or 7 or 
any 3 other questions [18]. 
An extra 2 questions were added for data gathering purposes: “11 – Do you undertake testosterone 
replacement therapy at the moment?” and “12 – What is your height?”. 
From the 45 males, 6 were deceased, so the questionnaire was sent to 39 males. From those 39, 2 didn’t 
have a valid address or contact number and 3 didn’t answer from health conditions such as cerebral stroke 
and mental incapability. A total of 34 valid questionnaires were received. 
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The study protocol was approved by the Hospital Ethical Committee and all patients provided written 
informed consent. 
 
Statistical methods 
 
Descriptive characteristics of the study population were tabulated as mean (SD) or median (minimum and 
maximum) according to the variables distribution, or proportions, as applicable. Student’s t-test or Mann-
Whitney U test were computed to compare the distributions of continuous variables between two 
independent samples. Differences of proportions among groups of patients were calculated with chi-
square test or Fisher test as appropriate. The significance level was set at 5%. 
 
Results 
Of the 109 patients, 62 (33 males and 29 females) underwent one or more surgeries, with or without 
radiotherapy, but 3 (1 male and 2 females) lacked follow-up data, one of which due to the patient’s death. 
The mean age at diagnosis was 51.8 years ± 17.26 (ranging from 18 to 91).  
The population of NFPA was formed by 64 (59%) females and 45 (41%) males. Most tumors were 
macroadenomas, 73 (67%) vs 36 (33%) microadenomas (p=0.001). Of the males, 40 (88%) had 
macroadenomas and 5 (12%) had microadenomas (p<0.001). Of the females, 33 (52%) had 
macroadenomas and 31 (48%) had microadenomas. Of the patients with macroadenomas 40 (55%) were 
males and 33 (45%) were females, but there is a different proportion of macroadenomas on males and 
females (88% vs 55%) (p<0.001).  The median age of patients with microadenoma was 39 years (18-84), 
and the median age for macroadenomas was 59 years (24-91) (p<0.001). Only a minority was incidentally 
diagnosed, a total of 21 (19%) (p<0.001), of the females 12 (20%) and of the males 8 (18%). The median 
age of patients incidentally discovered was 58 years (34-84), and the median age for patients diagnosed 
when investigating symptoms related to the pituitary adenoma was 49 years (18-91). Of the 
incidentalomas, 11 (52%) were macroadenomas and 10 (48%) were microadenomas. Of the patients 
diagnosed when investigating symptoms (88 patients, 81%), 62 (70%) were macroadenomas and 26 
(30%) were microadenomas. 
 
Hormonal analysis: 
 
On the pre-intervention evaluation, of the 109 patients, 66 (60%) were normal and 43 (40%) were HH. Of 
the 45 males, 18 (40%) were normal and 27 (60%) had HH. Of the 64 females, 48 (75%) were normal and 
16 (25%) had HH. From the female normal group 32 (66%) were pre-menopause and 16 (33%) were 
post-menopause. Males underwent more surgery than females (60 vs 25%) (p<0.001). Of the 
macroadenomas, 39 (47%) had HH and 34 (53%) didn’t, and of the microadenomas, 4 (11%) had HH and 
32 (89%) didn’t (p<0.001). Of the non-incidentalomas, 39 (44%) were HH and 49 (56%) weren’t, and of 
the incidentalomas, 4 (19%) were HH and 17 (81%) weren’t (p=0.03). There was a positive response to 
the GnRH test in 17 of the 30 patients (57%). Of the males 10 (47%) responded and of the females 7 
(78%). There was difference between male and female age at diagnosis (58.1 vs 47.4) (p=0.001). Males 
were significantly older, more hypogonadal, more surgically or radiotherapy treated. 
All patients submitted to radiotherapy had previously undergone surgery. Median of age of patients that 
were submitted to surgery was 56 years (24-82) and median age for patients that didn’t have surgery was 
45.5 years (18-91). Of the males, 32 (71%) had surgery, 9 (50%) from the normal group and 23 (85%) 
from the HH group. Of the females, 27 (42%) had surgery, 16 (33%) from the normal group and 11 
(69%) from the HH group. From the normal group 9 (56%) were pre-menopause and 7 (44%) were post-
menopause. There was a difference between the number of males that underwent surgery and the females 
(71% of males, 42% of females) (p=0.03).  Which translates that of the 59 patients that had surgery 32 
(54%) were males and 27 (46%) were females. 
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Table 1: Clinical characteristics of the sample 
 
 
Males 
(n=45) 
Females 
(n=64) 
Total 
(n=109) 
Mean age in years 
mean ± STD (range) 
58.1 ±15.86* (20-91) 47.4±16.94* (18-80) 51.8±17.26 (18-91) 
Mean BMI 
mean ± STD 
27.5± 3.86 28.2±5.71 27.9 ± 5.00 
Hypogonadism 
n (%) 
27 (60)
 
* 16 (25)
 
* 43 (40) 
Surgery 
n (%) 
32 (71) *
 
27 (42)
 
* 59 (54) 
Radiotherapy 
n (%) 
7 (16) 0 7 (6) 
Macroadenomas 
n (%) 
40 (88) *  33 (52) 73 (67) * 
Incidentalomas 
n (%) 
8 (18) 13 (20) 21 (19) * 
*
marks statistically significant values 
 
 
Of the patients that had surgery, 57 (97%) were macroadenomas and 2 (3%) were microadenomas 
(p<0.001). Of the macroadenomas 57 (78%) had surgery and of the microadenomas 2 (6%) had surgery 
(p=0.001). Of the patients that had surgery, 4 (7%) were incidentally discovered and 55 (93%) were 
diagnosed based on symptoms (p<0.001). Of the patients that were incidentally discovered only 4 (19%) 
had surgery (p<0.001) and of the non-incidentalomas 55 (63%) had surgery (p<0.001). This information 
is show on table 2. 
 
 
Table 2: Tumor size and diagnosis relation with surgery 
 
Surgery 
(n=59) 
n (%) 
Median age  
in years 
median (range) 
Macroadenomas (n=73) 57 (78)* 59 (24-91)* 
Microadenomas (n=36) 2 (6)* 39 (18-84)* 
Incidentalomas (n=21) 4 (19)* 58 (34-84) 
Non-incidentalomas (n=88) 55 (63)* 49  (18-91) 
*
marks statistically significant values 
 
 
Of the males a total of 3 (9%) worsened (patients with previous normal pituitary function that became HH 
after surgery), 6 (19%) improved (patients with previous HH, gained normal pituitary function after 
surgery) and 23 (72%) maintained the previous pituitary gonadotropic function (either normal or HH).  
Of the normal females who were in pre-menopause, 7 (77%) maintained normal function and 2 (23%) 
worsened becoming HH. Of the normal females who were post-menopause, 4 (57%) maintained normal 
function and 3 (43%) worsened. In total, of the normal females intervened, 11 (69%) maintained normal 
function and 5 (31%) worsened. Of the HH females intervened, 4 (36%) improved for normal function (3 
(75%) were pre-menopause and 1 (25%) was post-menopause) and 7 (64%) maintained HH. Of the 
females a total of 5 (18%) worsened, 4 (15%) improved and 18 (67%) maintained the previous pituitary 
gonadotropic function.  
In total of patients, 8 (14%) worsened, 17 (29%) maintained normal function, 24 (41%) maintained HH 
and 10 (17%) improved pituitary gonadotropic function (statistically significant) (table 4).  
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After surgery, of the macroadenomas 34 (60%) had HH and 23 (40%) didn’t, and of the microadenomas, 
both patients didn’t have HH. Of the non-incidentalomas, 33 (60%) had HH and 22 (40%) didn’t, and of 
the incidentalomas, 1 (25%) had HH and 3 (75%) didn’t.  Of the patients that had surgery only 2 had 
microadenomas and both maintained normal function and of the patients with macroadenomas 8 (14%) 
worsened, 10 (18%) improved and 39 (68%) maintained previous function.  
Prevalence of HH before and after surgery is shown on table 3.  
There was a positive response to the GnRH test after surgery in 9 of the 17 patients (53%). Of the males 5 
(55%) responded and of the females 4 (50%) (table 5). 
 
 
Table 3: Hypogonadotropic hypogonadism prevalence 
 
 
Males 
n (%) 
Females 
n (%) 
Total 
n (%) 
 
(n=45) (n=64) (n=109) 
Before/without surgery 27 (60)* 16 (25)* 43 (40) 
 
 
 
(n=32) (n=27) (n=59) 
Before and with surgery 23 (72) 11 (41) 34 (58) 
After surgery 20 (62) 12 (44) 32 (54) 
*
marks statistically significant values 
 
 
Table 4: Post-surgery outcome  
 
  
Improved 
n (%) 
Maintained 
Normal 
n (%) 
Maintained 
HH 
n (%) 
Worsened 
n (%) 
Total 
n (%) 
Males 6 (60) 6 (35) 17 (71) 3 (38) 32 (54) 
Females 4 (40) 11 (65) 7 (29) 5 (62) 27 (46) 
Total * 10 (17) 17 (29) 24 (41) 8 (13) 59 (100) 
*
marks statistically significant values 
 
 
Table 5: GnRH test on patients with hypogonadotropic hypogonadism 
 
Positive response 
Males 
n (%) 
Females 
n (%) 
Total 
n (%) 
Before surgery 
(n=21) (n=9) (n=30) 
10 (48) 7 (78) 17 (57) 
After surgery 
(n=9) (n=8) (n=17) 
5 (56) 4 (50) 9 (53) 
 
Some of the patients had to be re-intervened after the first surgery. There were statistically significant 
differences between the groups with different number of surgeries. The outcome of these patients is 
shown on table 6.  
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Table 6: Outcome of patients according to number of surgeries (statistically significant) 
 
 
 
 
 
 
 
 
 
 
 
There was no statistically significant difference of outcome with age, gender, menopause or radiotherapy. 
The variation of the BMI before and after surgery according to their PGS is show on table 7. After 
surgery, patients with hypogonadism had a higher BMI than normal patients, but these results weren’t 
statistically significant (table 7). Their evolution with outcome is shown on table 8.  
 
 
Table 7: Median Body Mass Index of all groups 
      
BMI  
median (range) 
Before 
surgery 
All patients (n=87) 
Normal (n=52) 26.4 (18.4 – 40.6) 
HH (n=35) 27.5 (21.0 – 45.9) 
Patients that had 
surgery (n=52) 
Normal (n=19) 25.8 (19.9 – 40.6) 
HH (n=28) 27.9 (21.4 – 35.3) 
After surgery (n=52) 
Normal (n=22) 27.3 (21.3 – 42.7) 
HH (n=30) 29.4 (22.8 – 35.0) 
 
 
 
Table 8: BMI of patients after surgery (n=52) and its association with outcome 
  Improved Maintained  Worsened 
Median BMI 
median (range) 
27.1 (23.3-29.1) 27.6 (21.4-42.7) 30.0 (22.8-32.6) 
 
 
 
Erectile Dysfunction questionnaire analysis: 
 
Of the 34 valid questionnaires received, 28 (82%) had had surgery and 18 (53%) had HH. After the 
analysis of the questionnaires, 26 (76%) had symptoms of ED and 14 (21%) reported doing TRT. The 
median age of the population was 62 years (range 23-88). The median age of the males with ED was 65 
and of the males without ED was 49, this difference was statistically significant. BMI of the groups is 
shown on table 9 and the median age on figure 1. 
 
 
 
 
 
 
 
  
Number of 
Surgeries 
Number of 
patients 
n (%) 
Improved or 
maintained 
n (%) 
Worsened 
n (%) 
1 50 (85) 44 (88) 6 (12) 
2 6 (10) 6 (100) 0 
3 3 (5) 1 (33) 2 (67) 
Total 59 51 (86) 8 (14) 
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Table 9: Characteristics of the male population that answered the ADAM questionnaire 
 
 
 
Number 
n (%) 
Median BMI 
median (range) 
Total 34 27.5 (20.8-36.5) 
Surgery 
with 28 (82) 28.0 (23.2-35.4) 
without 6 (18) 25.9 (20.8-36.5) 
Hypogonadism 
with 18 (53) 27.7 (24.3-35.0) 
without 16 (47) 27.1 (20.8-36.5) 
Erectile dysfunction 
with 26 (76) 27.8 (23.2-36.5) 
without 8 (24) 27.2 (20.8-30.3) 
Testosterone 
Replacement Therapy 
with 14 (21) 28.0 (23.2-32.5) 
without 20 (79) 27.4 (20.8-36.5) 
*
marks statistically significant values 
 
Patients with erectile dysfunction had a significantly higher age.  
 
Figure 1: Median age of the male population that answered the ADAM questionnaire 
 
*
marks statistically significant values 
 
The results obtained from the questionnaires are shown on table 10. There were no statistically significant 
associations between the variables. 
Table 10: Associations between hypogonadism, erectile dysfunction and testosterone replacement 
therapy 
 
 
  
Surgery  
n (%) 
Hypogonadism  
n (%) 
Erectile 
dysfunction n (%) 
Testosterone 
Replacement Therapy  
n (%) 
 
with without with without with without with without 
Surgery 
with(n=28)     17 (61) 11 (39) 22 (79) 6 (21) 13 (46) 15 (54) 
without(n=6)     1 (17) 5 (83) 4 (67) 2 (33) 1 (17) 5 (83) 
Hypogonadism 
with(n=18) 17 (94) 1 (6)     14 (77) 4 (23) 10 (55) 8 (45) 
without(n=16) 11 (69) 5 (31)     12 (75) 4 (25) 4 (25) 12 (75) 
Erectile 
dysfunction 
with(n=26) 22 (85) 4 (15) 14 (54) 12 (46)     11 (42) 15 (58) 
without(n=8) 6 (75) 2 (25) 4 (50) 4 (50)     3 (38) 5 (62) 
Testosterone 
Replacement 
Therapy 
with(n=14) 13 (93) 1 (7) 10 (71) 4 (29) 11 (79) 3 (21)     
without(n=20) 15 (75) 5 (25) 8 (40) 12 (60) 15 (75) 5 (25)     
51 
56 
49* 
68 
62.5 62.5 
65* 
57.5 
0
10
20
30
40
50
60
70
Surgery Hypogonadism Erectile
Dysfunction
Testosterone
Replacement
Therapy
Median age (years) 
with
without
 
 
10 
 
Discussion 
The population had a slight female predominance, 59% vs 41% males, which is coincident with previous 
studies [14]. The mean age at diagnosis was 51.8 years, supporting the previous data of the NFPA being 
frequent on the elderly. In this sample most patients were over 40 years old (71%) [7,19]. Females were 
younger than males (table 1). Most tumors were macroadenomas (67%, p=0.001) and proportionally 
males had more macroadenomas than females (88% vs 55%) (p<0.001). In Drange’s, 77% of NFPA had 
macroadenomas and males had more frequently macroadenomas than females (92% vs 68%), and even 
though all these compared prevalences are higher than in our study, the tendency is similar to ours [14]. 
Patients with macroadenomas were older than patients with microadenomas (median 39 vs 59) (p<0.001). 
Patients diagnosed incidentally are much less common (19%, p<0.001) and seem to be older (58 vs 49 
years), but this wasn’t statistically significant. Of the non-incidentalomas, most of them were 
macroadenomas (70%), just like in the whole population, and, proportionally, there is a higher number of 
microadenomas on the incidentally discovered group than the whole population (48% vs 33%), but this 
isn’t statistically significant. 
Patients that had surgery seem to be older (median 56 vs 45.5 years), but this tendency is not statistically 
significant. Our sample has a similar number of patients intervened to other studies: 54% had surgery and 
6% had radiotherapy [20]. There is a statistical difference between males and females on this distribution 
(71% of the males vs 42% of the females had surgery, respectively), which could be attributed to a 
highest rate of incidentally discovered NFPA on females, that are frequently less severe and less likely to 
have surgery. Most patients that had surgery were macroadenomas (97%, p<0.001) and most 
macroadenomas had surgery (78%, p=0.001). Of the patients that didn’t have surgery, most of them were 
microadenomas (68%, p<0.001) and only a minority of microadenomas had surgery (10%, p=0.001). Of 
the incidentalomas only a minority had surgery (19%, p<0.001) and of the patients that didn’t have 
surgery, 34% were incidentalomas vs 7% on the group that had surgery. But this difference wasn’t 
statistically significant..  
The prevalence of HH on our population was 40%, which is within the range found on previous studies 
(26% – 72.6%) [7,19-21]. The prevalence of HH was higher on males than females, both before and after 
surgery, 60 vs 25% and 62 vs 44%, respectively, but only the difference before surgery was statistically 
significant. There was no statistically significant improvement with surgery (only 17%) and some even 
became HH having previous normal PGS (13%), which is in agreement with other studies [19-21]. 
Comparing males with females, 19% of the males improved vs 15% of females; 9% of the males 
worsened vs 18% of the females. Therefore, of the patients that improved, 40% were females vs 60% 
males and of those who worsened 62% were females vs 38% males. There seems to be a tendency for 
female patients to be more likely to worsen and less likely to improve than males (results not statistically 
significant). 
HH was less frequent on microadenomas (11% had HH and 89% didn’t) (p<0.001). Patients incidentally 
diagnosed most frequently had normal PGS (81%, p=0.003). After surgery, there was a slight increase in 
HH on macroadenomas (47% before surgery vs 60% after surgery). Both microadenomas operated 
remained normal PGS and there was no difference of outcome on macroadenomas comparing with the 
whole population operated.  
When comparing with other pituitary adenomas populations, there are other causes for HH besides those 
of NFPA, such as direct hormonal interaction. On acromegaly, the mean age at diagnosis is 41-45 years, 
which is lower than that of NFPA, most patients had macroadenomas (77-86%), which was higher than in 
our series of NFPA (67%), but we had different proportion of macroadenomas in males vs females (88 vs 
52%), unlike acromegaly, in which patients had a similar macroadenoma distribution according to gender 
[14,22-24]. The prevalence of HH before intervention (surgery, radiotherapy or pharmacological 
treatment) is 53%, 46-53% on males and 46-60% on females, which is similar to that of NFPA 
[22,23,25]. The outcome varies significantly with the series and treatment approach, iatrogenic HH as low 
as 4.9% and as high as 41% [24,26-28]. Prolactinomas are more frequent on females, as seen on NFPA, 
and the mean age at diagnosis is lower on females than males (32.7 vs 41.6), which is still lower than the 
mean age at diagnosis made on NFPA [14,29]. The treatment of prolactinomas is in most cases 
pharmacological, but some patients are subjected to surgery. On Maric’s study, 45% of the patients with 
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prolactinomas had HH and with surgical approach there was a 20% improvement. In this study, most 
patients had microadenomas, only 36% were macroadenomas, which is the opposite proportion that we 
observe in NFPA, but on other study the prevalence of macroadenomas on prolactinomas can go up to 
50%, which is still not the majority, as seen on NFPA [14,29]. Like in our series of NFPA, on 
prolactinomas males seem to have more frequently macroadenomas than females (74% vs 40%) [14]. 
Even though there was a high rate of positive responses to the GnRH test (57% before surgery and 53% 
after surgery), besides lacking data on a high number of patients (and different missing data numbers on 
males vs females), no important information could be attained from these results. Even though this 
information would suggest that the HH on these patients was from hypothalamic and not pituitary causes 
on approximately half the sample, this test is neither sensitive nor specific for HH and positive response 
doesn’t exclude nor ascertains pituitary or hypothalamic pathology, due to highly variable responses to 
GnRH stimulation [30,31]. Therefore the clinical importance of this test to HH diagnosis seems to be 
obsolete, as it was reported previously [32]. 
Reoperation was done once on 10% of patients and twice on 5%, which is a slightly lower number than 
other studies (19% had 2 surgeries and 9% had 3 surgeries) [20]. Even though there was a statistically 
significant difference of outcome between the groups of different number of interventions, there isn’t a 
tendency of increasing number of surgeries associated with worst prognosis, such information would only 
be supported comparing the group with 1 surgery and 3 surgeries. The increasing number of surgeries 
should be associated with increasing risk of iatrogenic HH. Nonetheless, the indication for surgery is 
often insufficient tumor removal on previous surgery or regrowth than presence of HH, which can cause 
different characteristics on the patients that undergo different number of surgeries, such as bigger tumors 
or more symptoms, information that is not accounted in this study and that associated with a small sample 
of patients, results in an impossibility to find that predictable causality of the iatrogenic effect. 
Other factors didn’t interfere in a statistically significant way on the outcome (such as age, gender or 
menopause).  
There was a tendency of higher BMI for patients with HH than with normal PGS in all groups (before and 
after surgery). There was a tendency of increasing BMI from best to worst outcome: 27.1<27.6<30.0 for 
the improved (regained normal pituitary function), maintained previous pituitary function (either normal 
or HH) and worsened (became HH after surgery) groups, respectively. Despite these tendencies, these 
findings weren’t statistically significant.  
 
Most of the patients that answered the questionnaire had had surgery (82%) and about half had 
hypogonadism (53%). Patients that didn’t have surgery had less HH (83%), which can arise from the fact 
that they probably had less severe symptoms or smaller tumors, that interfere less with adjacent structures 
(which reduces the probably of HH on NFPA patients), and don’t have indication for surgery at the 
moment. This makes it expected that patients that had surgery had more HH (94%), more ED (85%) and 
were more frequently under TRT (93%) than those who didn’t have surgery.  
On the questionnaires analysis, we observed a tendency for patients that didn’t undergo surgery or 
patients without HH being younger (51 vs 62.5 years and 56 vs 62.5 years, respectively). The presence of 
ED also followed this tendency and the difference in the median age was statistically significant between 
patients with and without ED (65 vs 49 years, respectively). There was a high prevalence of ED on our 
sample (76%), superior to the prevalence of HH (53%). Even though hypogonadism is a cause of ED, this 
difference on prevalences is most likely due to the high prevalence of older patients on the males 
subjected to the questionnaire (median 62 years) which is a known major risk factor for ED [33]. 
Therefore 46% of the patients with ED didn’t have HH, being the ED from other causes.  
Only 55% of the patients with HH were under TRT, even if TRT replaces testosterone that should be 
produced on the end of the gonadal axis, which is damaged on HH. Also, patients under TRT were 
younger than those without TRT, even though younger patients have less HH and ED. Both these results 
can be justified by the fact that older patients have more contraindications for TRT (such as prostate 
pathology, severe cardiovascular diseases) or less potential benefits from improving from ED due to 
advanced age, which can explain this apparent contradiction of highest prevalence of disease (HH and 
ED) corresponding to lower use of treatment (TRT).  
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As we said before, HH can lead to weight gain and therefore obesity, but  obesity is also a known factor 
for HH, so the causality relation between the two variables is unclear and may be a confunding factor [34-
36]. There was no statistically significant difference among the groups regarding BMI, even though 
patients that underwent surgery seem to have higher BMIs comparing with those who didn’t (28.0 vs 
25.9). Studies mention a consistent decrease in total body fat associated with TRT on HH males, but this 
fact was not observed on our sample [36]. Since our analysis of BMI and TRT is transversal and the 
duration of treatment was not recorded, this may be an important fact to cause dispersion of any tendency 
to lower BMI on patients with HH taking TRT. Simultaneously, the presence of ED on patients under 
TRT translates inefficient treatment (79% of patients under TRT still have ED). This, associated with the 
fact that even though TRT could reduce BMI, doesn’t improve cholesterol profile or have cardiovascular 
benefits, it makes us ponder the benefits of this treatment in comparison with its risks, especially since 
new studies suggest increased cardiovascular risk and all causes mortality on older patients, and on 
younger patients with pre-existing diagnosed heart disease, that do TRT [37-40]. 
 
 
Study limitations 
The small number of patients on our sample damaged our statistical power to show some statistically 
significant results. 
There are many confounding factors on the analysis of these results, since there is direct interference of 
the variables with one another, leading to blur on the tendencies and no statistical differences between the 
groups. For instance, patients with HH were treated with TRT, among other effects, to reduce ED, 
therefore the real prevalence of ED on patients with HH is underestimated.  
 
In conclusion, NFPA were more frequent on older patients. Male patients with NFPA were older, had 
more HH and surgery. There was no significant improvement of pituitary gonadotropin secretion with 
surgery (17%) and 13% had iatrogenic HH with surgery. TRT had a low efficacy to improve ED and 
change BMI in these patients 
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Appendix 
Table 11. Questions Used as Part of the Saint Louis University ADAM Questionnaire 
1. Do you have a decrease in libido (sex drive)? 
2. Do you have a lack of energy? 
3. Do you have a decrease in strength and/or endurance? 
4. Have you lost height? 
5. Have you noticed a decreased ‘‘enjoyment of life’’? 
6. Are you sad and/or grumpy? 
7. Are your erections less strong? 
8. Have you noted a recent deterioration in your ability to play sports? 
9. Are you falling asleep after dinner? 
10. Has there been a recent deterioration in your work performance? 
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 Identify any previously published material by giving the original source in the form of a 
reference at the end of the table caption. 
 Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for 
significance values and other statistical data) and included beneath the table body. 
 
Artwork and Illustrations Guidelines 
For the best quality final product, it is highly recommended that you submit all of your artwork – 
photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest 
standards with the greatest accuracy to detail. The published work will directly reflect the quality of the 
artwork provided. 
 
Electronic Figure Submission 
 Supply all figures electronically. 
 Indicate what graphics program was used to create the artwork. 
 For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS 
Office files are also acceptable. 
 Vector graphics containing fonts must have the fonts embedded in the files. 
 Name your figure files with "Fig" and the figure number, e.g., Fig1.eps. 
 
Line Art 
 
Definition: Black and white graphic with no shading. 
 Do not use faint lines and/or lettering and check that all lines and 
lettering within the figures are legible at final size. 
 All lines should be at least 0.1 mm (0.3 pt) wide. 
 Scanned line drawings and line drawings in bitmap format should 
have a minimum resolution of 1200 dpi. 
 Vector graphics containing fonts must have the fonts embedded in 
the files. 
 
 
 
Halftone Art 
 
 Definition: Photographs, drawings, or paintings with fine shading, etc. 
 If any magnification is used in the photographs, indicate this by using scale bars 
within the figures themselves. 
 Halftones should have a minimum resolution of 300 dpi. 
 
 
 
 
Combination Art 
 
 Definition: a combination of halftone and line art, 
e.g., halftones containing line drawing, extensive 
lettering, color diagrams, etc. 
 Combination artwork should have a minimum 
resolution of 600 dpi. 
 
Color Art 
 Color art is free of charge for online publication. 
 If black and white will be shown in the print version, make sure that the main information will 
still be visible. Many colors are not distinguishable from one another when converted to black 
and white. A simple way to check this is to make a xerographic copy to see if the necessary 
distinctions between the different colors are still apparent. 
 If the figures will be printed in black and white, do not refer to color in the captions. 
 Color illustrations should be submitted as RGB (8 bits per channel). 
 
Figure Lettering 
 To add lettering, it is best to use Helvetica or Arial (sans serif fonts). 
 Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–
12 pt). 
 Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an 
axis and 20-pt type for the axis label. 
 Avoid effects such as shading, outline letters, etc. 
 Do not include titles or captions within your illustrations. 
 
Figure Numbering 
 All figures are to be numbered using Arabic numerals. 
 Figures should always be cited in text in consecutive numerical order. 
 Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
 If an appendix appears in your article and it contains one or more figures, continue the 
consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." 
Figures in online appendices (Electronic Supplementary Material) should, however, be 
numbered separately. 
 
Figure Captions 
 Each figure should have a concise caption describing accurately what the figure depicts. Include 
the captions in the text file of the manuscript, not in the figure file. 
 Figure captions begin with the term Fig. in bold type, followed by the figure number, also in 
bold type. 
 No punctuation is to be included after the number, nor is any punctuation to be placed at the end 
of the caption. 
 Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as 
coordinate points in graphs. 
 Identify previously published material by giving the original source in the form of a reference 
citation at the end of the figure caption. 
 
Figure Placement and Size 
 When preparing your figures, size figures to fit in the column width. 
 For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not 
higher than 234 mm. 
 For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher 
than 198 mm. 
 
Permissions 
If you include figures that have already been published elsewhere, you must obtain permission from the 
copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant 
electronic rights for free and that Springer will not be able to refund any costs that may have occurred to 
receive these permissions. In such cases, material from other sources should be used. 
 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your figures, please make 
sure that  
 All figures have descriptive captions (blind users could then use a text-to-speech software or a 
text-to-Braille hardware) 
 Patterns are used instead of or in addition to colors for conveying information (color-blind users 
would then be able to distinguish the visual elements) 
 Any figure lettering has a contrast ratio of at least 4.5:1 
 
Electronic Supplementary Material 
 
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary 
files to be published online along with an article or a book chapter. This feature can add dimension to the 
author's article, as certain information cannot be printed or is more convenient in electronic form. 
 
Submission 
 Supply all supplementary material in standard file formats. 
 Please include in each file the following information: article title, journal name, author names; 
affiliation and e-mail address of the corresponding author. 
 To accommodate user downloads, please keep in mind that larger-sized files may require very 
long download times and that some users may experience other problems during downloading. 
Audio, Video, and Animations 
 Always use MPEG-1 (.mpg) format. 
Text and Presentations 
 Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. 
 A collection of figures may also be combined in a PDF file. 
Spreadsheets 
 Spreadsheets should be converted to PDF if no interaction with the data is intended. 
 If the readers should be encouraged to make their own calculations, spreadsheets should be 
submitted as .xls files (MS Excel). 
Specialized Formats 
 Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex 
can also be supplied. 
Collecting Multiple Files 
 It is possible to collect multiple files in a .zip or .gz file. 
Numbering 
 If supplying any supplementary material, the text must make specific mention of the material as 
a citation, similar to that of figures and tables. 
 Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation 
(Online Resource 3)", “... additional data are given in Online Resource 4”. 
 Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. 
Captions 
 For each supplementary material, please supply a concise caption describing the content of the 
file.  
Processing of supplementary files 
 Electronic supplementary material will be published as received from the author without any 
conversion, editing, or reformatting.  
Accessibility 
In order to give people of all abilities and disabilities access to the content of your supplementary files, 
please make sure that  
 The manuscript contains a descriptive caption for each supplementary material 
 Video files do not contain anything that flashes more than three times per second (so that users 
prone to seizures caused by such effects are not put at risk) 
 
Scientific style 
 Please always use internationally accepted signs and symbols for units (SI units). 
 Generic names of drugs and pesticides are preferred; if trade names are used, the generic name 
should be given at first mention. 
Integrity of research and reporting 
 
Ethical standards 
Manuscripts submitted for publication must contain a declaration that the experiments comply with the 
current laws of the country in which they were performed. Please include this note in a separate section 
before the reference list.  
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